New approaches to prophylaxis of endometrium hyperplasia relaps in premenopausal women




endometrial hyperplasia, metabolic syndrome, premenopausal period, Depapilin


Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial hyperplasia recurrence in premenopausal women.
Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment.
Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p <0.05). The positive treatment effect consisted in a significant decrease in the frequency of endometrial hyperplasia recurrence, which was 17 (17.5%) cases in the main group and 16 (44.4%) cases in the comparison group (p <0.05). Women of the main group also showed stable normalization of the level of estrogen and progesterone, a steady decrease in the level of homocysteine and a synergistic increase in the level of folic acid, normalization of blood pressure and reduction of body mass index.
Conclusions. Depapilin® inclusion in the basic therapy of endometrial hyperplasia in premenopausal aged women is pathogenetically justified due to the complex effect of the drug components on the extragonadal estrogens synthesis and the antiproliferative effect on the endometrium.

Author Biographies

V.O. Beniuk, National Medical University named after A.A. Bogomolets

MD, professor, head of the Obstetrics and Gynaecology Department No. 3

V.H. Ginzburg, Bogomolets National Medical University

MD, associate professor, professor, Obstetrics and Gynaecology Department No. 3

D.O. Govsieiev, Institute of Postgraduate Education, Bogomolets National Medical University

MD, professor, Department of Obstetrics and Gynecology

V.F. Oleshko, Bogomolets National Medical University

PhD, assistant, Obstetrics and Gynecology Department No. 3

T.V. Kovaliuk, Bogomolets National Medical University

PhD, assistant professor, Obstetrics and Gynaecology Department No. 3

Y.V. Kravchenko, Bogomolets National Medical University

Graduate student, Obstetrics and Gynecology Department No. 3

A.S. Luchko, Bogomolets National Medical University

Graduate student, Obstetrics and Gynecology Department No. 3


  1. Bakhtijarov, K.R. “A new approach to the treatment of pathological conditions of the uterine cavity.” In: New technologies in obstetrics and gynecology. Moscow (1997): 19–21.
  2. Gabidullina, R.I., Smirnova, G.A., et al. “Hyperplastic endometry processes: modern patient management tactics”. Consilium Medicum 21.6 (2019): 53–8.
  3. Zhuk, S.I. “Algorithms for helping with abnormal uterine bleeding”. Female Doctor 4 (2015): 22–31.
  4. Zaichenko, G.V., Gorchakova, N.O., Sinicyna, O.S., et al. “Pharmacodynamics and spectrum of action of indole-3-carbinol.” Bulletin of problems of biology and medicine 3.145 (2018): 30–8.
  5. Kappusheva, L.M. Endometrial polyps (diagnosis, tactics, treatment). Endoscopy in gynecology. Moscow. Medicine (2016): 594 p.
  6. Lebedev, V.A. Clinical and pathogenetic variants of endometrial polyps and modern approaches to their treatment. Results and achievements of scientific research in gynecology. Moscow (2016): 167–72.
  7. Manukhin, I.B., Tumilovich, L.G., Gevorkjan, M.A. Clinical lectures on gynecological endocrinology. Moscow. MIA (2017): 131 p.
  8. Prokopiuk, O.S. “Oncogenic risk associated with obesity in perimenopausal women.” Kharkiv surgical school 6 (2014): 97–100.
  9. Serov, V.N., Prilepskaja, V.N., Pshenichnikova, T.Y. Practical guide to gynecological endocrinology. Moscow. Rusfarmamed (2015): 427 p.
  10. Tatarchuk, T.F., Pedachenko, N.Y., Homіnska, Z.B. “Metabolic syndrome and endometrial hyperproliferative processes.” Reproductive endocrinology 2.16 (2014): 61–72.
  11. Tkachenko, L.V., Sviridova, N.I. “Hyperplastic processes of endometry in premenopause: modern possibilities of hormonal correction and prevention.” Gynecology 15.2 (2013): 8–12.
  12. de Villiers, T., Tatarchuk, T.F. “National consensus on the management of menopausal patients.” Reproductive endocrinology 1.27 (2016): 8–25.
  13. Afshin, A., Forouzanfar, M.H., et al. “Health effects of overweight and obesity in 195 countries over 25 years. GBD 2015 Obesity Collaborators.” N Engl J Med 377.1 (2017): 13–27.
  14. Armstrong, A.J., Hurd, W.W., Elguero, S., et al. “Diagnosis and Management of Endometrial Hyperplasia.” J Minim Invasive Gynecol 19.5 (2012): 562–71.
  15. Clark, T.J., Stevenson, H. “Endometrial Polyps and Abnormal Uterine Bleeding (AUB-P): What is the relationship, how are they diagnosed and how are they treated?” Best Pract Res Clin Obstet Gynaecol 40 (2016): 89–104.
  16. Inoue, M. “Current molecular aspects of the carcinogenesis of the uterine endometrium.” Int J Gynecol Cancer 11 (2017): 339–48.
  17. Jae Kwang Kim, Sang Un Park. “Current results on the biological and pharmacological activities of indole-3-carbinol.” EXCLI Journal 17 (2018): 181–5.
  18. Kim, E.K., Kim, Y.S., Milner, J.A., Wang, T.T. “Indole-3-carbinol and 3’,3’– diindolylmethane modulate androgen’s effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells.” Cancer Prev Res (Phila) 6.6 (2013): 519–29.
  19. Podzolkova, N.M., Tatarchuk, T.F., Doshchanova A.M., et al. “Menstrual cycle normalization with dydrogesterone.” Akusherstvo i Ginekologiya (Russian Federation) 6 (2018): 70–5.
  20. Royal College of Obstetrician and Ginecologists. Management of Endometrial Hyperplasia. GreenTop Guideline No. 67 (2016).
  21. Scheuer, S.H., Færch, K., Philipsen, A. “Abdominal fat distribution and cardiovascular risk in men and women with different levels of glucose tolerance.” J Clin Endocrinol Metab 100.9 (2015): 3340–7. DOI: 10.1210/JC.2014-4479
  22. Sobczuk, K., Sobczuk, A. “New classification system of endometrial hyperplasia WHO 2014 and its clinical implications.” Prz Menopauzalny 16.3 (2017): 107–11.
  23. Wise, M.R., Jordan, V., Lagas, A., et al. “Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review.” Am J Obstet Gynecol 214.6 (2016): 689–97.
  24. Yati, M., Susilowati, A. “Changes in folate characteristics and its identification in broccoli (Brassica oleracea Italica) extract fermented by Lactic Acid Bacteria Mixed Culture (LAB).” MATEC Web of Conferences 154.2 (2018): 04001. DOI: 10.1051/matecconf/201815404001
  25. Zhang, H., Sairam, M.R. “Sex hormone imbalances and adipose tissue dysfunction impacting on metabolic syndrome; a paradigm for the discovery of novel adipokines.” Horm Mol Biol Clin Investig 17.2 (2014): 89–97.



How to Cite

Beniuk, V., Ginzburg, V., Govsieiev, D., Oleshko, V., Kovaliuk, T., Kravchenko, Y., & Luchko, A. (2021). New approaches to prophylaxis of endometrium hyperplasia relaps in premenopausal women. REPRODUCTIVE ENDOCRINOLOGY, (58), 63–72.



Management of menopause